Phosphotyrosine profiling of curcumin-induced signaling

Gajanan Sathe1,2†, Sneha M. Pinto1,3†, Nazia Syed1,4, Vishalakshi Nanjappa1,5, Hitendra S. Solanki1,6, Santosh Renuse1,5, Sandip Chavan1,2, Aafaque Ahmad Khan1,6, Arun H. Patil1,6, Raja Sekhar Nirujogi1,7, Bipin Nair5, Premendu Prakash Mathur6, T. S. Keshava Prasad1,3,8, Harsha Gowda1,3* and Aditi Chatterjee1,3*

Abstract

Background: Curcumin, derived from the rhizome Curcuma longa, is a natural anti-cancer agent and has been shown to inhibit proliferation and survival of tumor cells. Although the anti-cancer effects of curcumin are well established, detailed understanding of the signaling pathways altered by curcumin is still lacking. In this study, we carried out SILAC-based quantitative proteomic analysis of a HNSCC cell line (CAL 27) to investigate tyrosine signaling in response to curcumin.

Results: Using high resolution Orbitrap Fusion Tribrid Fourier transform mass spectrometer, we identified 627 phosphotyrosine sites mapping to 359 proteins. We observed alterations in the level of phosphorylation of 304 sites corresponding to 197 proteins upon curcumin treatment. We report here for the first time, curcumin-induced alterations in the phosphorylation of several kinases including TNK2, FRK, AXL, MAPK12 and phosphatases such as PTPN6, PTPRK, and INPPL1 among others. Pathway analysis revealed that the proteins differentially phosphorylated in response to curcumin are known to be involved in focal adhesion kinase signaling and actin cytoskeleton reorganization.

Conclusions: The study indicates that curcumin may regulate cellular processes such as proliferation and migration through perturbation of the focal adhesion kinase pathway. This is the first quantitative phosphoproteomics-based study demonstrating the signaling events that are altered in response to curcumin. Considering the importance of curcumin as an anti-cancer agent, this study will significantly improve the current knowledge of curcumin-mediated signaling in cancer.

Keywords: Oral cancer, Phosphoproteomics, In vivo labeling, Curcumin

Background

Curcumin, a bioactive compound derived from the rhizome Curcuma longa has been known for its chemopreventive and chemotherapeutic potential [1, 2]. It is a polyphenol compound with an aromatic ring structure connected by two α, β-unsaturated carbonyl groups and has been extensively studied for its diverse range of biological activities, including anti-inflammatory, antioxidant, analgesic and antiseptic properties [3–6]. It has attracted widespread attention as a potential therapeutic agent because of its pharmacological effects. The anti-tumor activity of curcumin is thought to be mediated through multiple mechanisms. At the molecular level, curcumin is known to induce apoptosis in a wide array of cancer cells including human colon, stomach, liver, breast, and prostate cancers [7–11]. It is known to mediate its effects by inhibition of anti-apoptotic markers such as Bcl-2, Bcl-xL, Survivin, and increased expression of pro-apoptotic factors such as Bax, Bad, Bak, PUMA, Bim, Noxa and TRAIL-R1 [12–14]. Curcumin has also been shown to inhibit cellular proliferation by downregulating several oncogenes such as EGFR, HER-2, PI3K/AKT, MAPK and upregulating the expression of various tumor suppressor genes such as p21WAF1/CIP1, p27KIP1 and...
p53 [15–19]. Furthermore, in vivo studies using animal models of skin and oral cancer have shown that curcumin inhibits tumor initiation and progression [20, 21].

Curcumin mediates its effect by targeting multiple cell growth signaling pathways, including PI3K-AKT, mTOR, EGFR and TGF-β signaling, amongst others [22–25]. It has been reported to cause a dose and time-dependent decrease in the phosphorylation of AKT and mTOR leading to decreased cellular proliferation and survival [26]. Curcumin has also been reported to induce the suppression of NF-κB and IKK activation in melanoma cells and inhibit JNK signaling and STAT3 activation which in turn decreases the expression of pro-survival proteins [27–29]. Currently, information pertaining to curcumin-mediated tyrosine phosphoproteome signaling is minimal and the detailed signaling mechanism responsible for various biological effects of curcumin remains elusive. Understanding the signaling pathways responsible for its anti-neoplastic activity will provide avenues to identify novel therapeutic targets for cancers.

Aberrant activation of signaling pathways mediated by kinases is a common phenomenon in multiple malignancies. Tyrosine kinases regulate various cellular processes such as cell proliferation, differentiation, motility, cell cycle homeostasis, transcriptional regulation, and metabolism through reversible phosphorylation [30]. Although several studies have been carried out to characterize curcumin-induced alterations in cellular proteome of neuroblastoma [31], breast [32], gastric [11] and cervical cancers [33]; no effort have been made to study the changes in tyrosine signaling mediated by curcumin using quantitative phosphoproteomics approach.

In this study, we carried out SILAC-based quantitative proteomic analysis of CAL 27 cells (a HNSCC cell line) to investigate the tyrosine signaling in response to curcumin. Previous studies have reported curcumin-induced apoptosis and decreased cell proliferation in CAL 27 [34, 35]. Combining SILAC with anti-phosphotyrosine antibody-based enrichment and high resolution mass spectrometry analysis enabled identification of 627 unique phosphorylation sites mapping to 359 proteins including several novel curcumin-regulated phosphorylation events. Further, bioinformatics analysis identified perturbations in pathways regulating focal adhesions and actin cytoskeleton in curcumin-treated cells suggesting that curcumin may mediate its anti-proliferative effects through these pathways.

Methods

Reagents

Anti-phosphotyrosine rabbit monoclonal antibody (P-Tyr-1000) beads, MAPK, EPHA2 antibody were obtained from Cell Signaling Technology (Danvers, MA) and 4G10 anti-phosphotyrosine (HRP conjugated) antibody was purchased from Millipore (Billerica, MA). Curcumin was purchased from Sigma (St. Louis, MO). TPCK-treated trypsin was from Worthington Biochemical Corp. (Lakewood, NJ). DMEM with and without lysine and arginine, fetal bovine serum (FBS), 1-glutamine, and antibiotics were purchased from Invitrogen (Carlsbad, CA). SILAC amino acids, 13C6-Lysine and 13C6-Arginine, were obtained from Cambridge Isotope Laboratories (Andover, MA). All other reagents used in this study were from Fisher Scientific (Pittsburgh, PA).

MTT cell proliferation assay

To determine the effect of curcumin on CAL 27 cells, MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) assay was carried out according to manufacturer’s protocol (ATCC 30-1010K). Briefly, cells were seeded at a density of 8 × 104 and treated with curcumin at varying concentration (0–25 µM) for 48 h. After incubation, MTT reagent was added and incubated for 2–4 h until the purple precipitate was formed. Purple crystals were solubilised using 100 µl of detergent solution and left at room temperature for 2 h. Further, the absorbance was read at 570 and 650 nm.

Cell culture and SILAC labeling

CAL 27 cells was obtained from American Type Culture Collection (ATCC, Manassas, VA). CAL 27 cells were maintained in a humidified incubator at 37 °C with 5 % CO2. The cells were cultured in DMEM containing heavy stable isotopic forms of lysine and arginine (13C6 l-lysine and 13C6 l-arginine), 10 % FBS and 1 % penicillin/streptomycin mixture (SILAC media). CAL 27 cells were also grown in regular DMEM containing 10 % FBS and 1 % penicillin/streptomycin mixture. When cells reached 70 % confluence, the cells were subjected to serum starvation for 8 h. Post-serum starvation, cells cultured in SILAC media were treated with DMSO and cells cultured in regular DMEM were treated with curcumin (11.5 µm) for 4 h. Following 4 h treatment, the cells from both conditions were washed with ice cold 1X phosphate buffer saline (PBS) thrice and harvested in lysis buffer.

Cell lysis and protein digestion

The DMSO (vehicle control) and curcumin treated CAL 27 cells were lysed in lysis buffer (20 mM HEPES pH 8.0, 9 M urea, 1 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate), sonicated and centrifuged at 16,000×g for 20 min. Protein concentration was determined using BCA assay (Pierce, Waltham, MA). Equal amounts of protein (20 mg) were mixed and the cysteine residues were reduced and
alkylated with 5 mM DTT for 20 min at 60 °C and 10 mM iodoacetamide for 10 min at room temperature respectively. For trypsin digestion, the samples were diluted such that urea was <2 M with 20 mM HEPES, pH 8.0 and subjected to digestion with TPCK treated trypsin (Worthington Biochemical Corp, Lakewood, NJ) for 12–16 h at room temperature. Protein digests were acidified by 1 % trifluoroacetic acid (TFA) and desalted using C18 Sep-Pak cartridge (Waters, Cat#WAT051910) and lyophilized.

**Immunooaffinity purification of tyrosine phosphopeptides**

The lyophilized peptide mixtures were dissolved in in IAP buffer containing 50 mM MOPS pH 7.2, 10 mM sodium phosphate and 50 mM NaCl. Prior to phospho-tyrosine enrichment, the P-Tyr-1000 beads (Cell Signaling Technology, Danvers, MA) were washed twice with IAP buffer at 4 °C. The peptide mixture was then incubated with P-Tyr-1000 beads for 30 min with gentle rotation. To remove non-specifically bound peptides, the beads were washed thrice with ice cold IAP buffer and twice with ice cold water. Elution of enriched peptides from beads was carried out at room temperature using 0.15 % TFA. This step was repeated twice. This was followed by clean up of the samples using C18 StageTips as described earlier [36].

**LC-MS/MS analysis of enriched peptides**

The enriched phosphotyrosine containing peptides were analyzed on Orbitrap Fusion Trisbrid mass spectrometer (Thermo Electron, Bremen, Germany) interfaced with Easy-nLC II nanoflow liquid chromatography system (Thermo Scientific, Odense, Denmark). Peptide digests were reconstituted in 0.1 % formic acid and loaded onto trap column packed (75 µm x 2 cm) with Magic C18 AQ (Michrom Bioresources, Inc., Auburn, CA) at a flow rate of 3µL/min. Peptides were separated on an analytical column (75 µm x 20 cm) at a flow rate of 400 nL/min using a step gradient of 5–25 % solvent B (0.1 % formic acid in 95 % acetonitrile) for first 110 min and 25–40 % solvent B for 110–140 min. The total run time was set to 180 min. Mass spectrometer was operated in data-dependent acquisition mode. A survey full scan MS (from m/z 350–1700) was acquired in the Orbitrap with resolution of 120,000 at 400 m/z. Most intense fifteen precursor ions with charge state ≥2 were isolated and fragmented using HCD fragmentation with 30 % normalized collision energy and detected at a mass resolution of 30,000 at 400 m/z. Dynamic exclusion was set for 30 s with a 10 ppm mass window.

**Data analysis**

The MS/MS searches were carried out using MASCOT (Version 2.2.0) and SEQUEST search algorithms against RefSeq human protein database (version 65 containing 34,453 entries with common contaminants) using Proteome Discoverer 1.4 (Version 1.4.0.288 Thermo Fisher Scientific, Bremen, Germany). The workflow for both algorithms included spectrum selector, MASCOT, SEQUEST search nodes, peptide validator, event detector, precursor quantifier, and phosphoRS nodes. Oxidation of methionine, phosphorylation at serine, threonine and tyrosine (+79.966 Da) and SILAC labeling (13C6) at lysine and arginine (+6.02013 Da) were set as variable modifications and carbamidomethylation of cysteine was set as a fixed modification. MS and MS/MS mass tolerances were set to 5 ppm and 0.025 Da, respectively. Trypsin was specified as protease and a maximum of one missed cleavage was allowed. Target-decoy database searches used for calculation of false discovery rate (FDR) and for peptide identification FDR was set at 1 %. Quantitation node was used for calculation of SILAC ratio for each phosphopeptide-spectrum match (phosphoPSM) and probability of the phosphorylation site was calculated using phosphoRS 3.1 node in the Proteome Discoverer. The SILAC ratios were normalized based protein median. Phosphopeptides with >75 % localization probability were considered for further analysis [37].

**Availability of data**

The mass spectrometry derived data have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner repository with the dataset identifier PXD002097.

**Bioinformatics analysis**

Molecular function of phosphoproteins was obtained from Human Protein Reference Database (HPRD) (http://www.hprd.org/) [38]. The differentially phosphorylated proteins upon curcumin treatment were mapped to gene networks available in Ingenuity Systems Pathway Analysis (IPA) platform (https://analysis.ingenuity.com) and ranked based on the score. Network analysis was performed with the significantly enriched genes. KEGG pathway mapping of curcumin-regulated phosphoproteins was performed using the DAVID bioinformatics functional annotation tool [39]. Identification of enriched motifs was carried out using motif-X algorithm [40]. A 15 amino acids phospho window was used for extracting consensus motif. The significance threshold was set to p < 0.02 and the minimum occurrence of motifs was set to 10.

**Western blot analysis**

CAL 27 cells were cultured in DMEM in 37 °C humidified 5 % CO2 incubator. The cells were serum starved for 8 h prior to curcumin treatment. The cells were
treated with either vehicle control (DMSO) or curcumin for 1 and 4 h. Cells were lysed in modified RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 % Nonidet P-40, 0.25 % sodium deoxycholate, and 1 mM sodium orthovanadate in the presence of protease inhibitors) followed by centrifugation. The protein lysates were resolved using SDS-PAGE and Western blot analysis was performed using phospho-tyrosine antibody 4G10. Western blot analysis were performed on CAL 27 lysate (untreated and curcumin treated) using anti-phospho and total MAPK1/MAPK3 and EPHA2 antibodies. β-actin was used as a loading control.

**Colony formation and invasion assays**

Colony formation and invasion assays were performed as described previously [42]. Briefly, CAL 27 cells were seeded at a density of 3 × 10^5 cells into a 6-well plate with complete media. After 24 h, cells were treated with curcumin and cells treated with DMSO served as control. Cell colonies were allowed to grow for 10 days. Then, the colonies were fixed using methanol and stained with 4 % methylene blue. The number of colonies per well were counted. All experiments were done in duplicate. All experiments were repeated thrice.

The effect of curcumin on the invasion potential of CAL 27 cells was assessed in vitro in a transwell system (BD Biosciences, San Jose, CA) using Matrigel coated filters as described previously [42]. DMSO and curcumin treated CAL 27 cells at a density of 2 × 10^4 were suspended in 500 µl of serum free media and seeded on the Matrigel-coated PET membrane in the upper compartment. The lower compartment was filled with complete growth media and the plates were incubated at 37 °C for 48 h. At the end of the incubation, the upper surface of the membrane was wiped with a cotton-tip applicator to remove non-migratory cells. Cells that migrated to bottom side of membrane were fixed and stained using 4 % methylene blue. Each measurement was performed in duplicate. All experiments were repeated thrice.

**Results and discussion**

**Curcumin inhibits cellular proliferation, invasion and colony forming ability of CAL 27 cells**

To determine the effect of curcumin on cell survival, CAL 27 cells were treated with curcumin at varying concentrations (0–25 µM) and subjected to MTT assay. CAL 27 cells showed a decrease in cell viability in presence of curcumin (Additional file 1: Fig.S1A). Next, we studied the colony forming ability of CAL 27 cells in presence of curcumin. There was a significant reduction in the colony forming ability of the cells in the presence of curcumin compared to control cells (Fig. 1a, b) (p value <0.005). We also observed a significant decrease in the invasive ability of CAL 27 cells upon curcumin treatment (Fig. 1c, d) (p value <0.001). Taken together, these results suggest that curcumin inhibits cellular proliferation and metastatic potential of CAL 27 cells.

**Quantitative phosphoproteomic analysis of curcumin induced signaling**

In order to characterize signaling mechanism through which curcumin functions, CAL 27 cells were treated with curcumin for different durations to identify the time point when tyrosine signaling is affected. An initial immunoblot analysis of tyrosine phosphorylation status in CAL 27 cells upon curcumin exposure for 0, 1 and 4 h indicated a moderate decrease in tyrosine signaling at 4 h of curcumin treatment (Fig. 1e). We investigated the molecular mechanism of curcumin-induced signaling using SILAC-based quantitative phosphoproteome analysis. Cells treated with DMSO (control cells) were adapted to ‘heavy’ SILAC media whereas the cells grown in ‘regular’ media were treated with curcumin for 4 h. Post curcumin treatment, the cells were lysed, equal amounts of lysates were pooled and digested with trypsin. The phosphotyrosine peptides were enriched by immunofinity purification and analyzed on Orbitrap Fusion Tribrid mass spectrometer. The schematic workflow of SILAC-based phosphoproteomics analysis is shown in Fig. 2.

LC-MS/MS analysis of phosphotyrosine enriched sample was carried out in triplicate and the acquired mass spectrometry data was processed and searched using MASCOT and SEQUEST search algorithms. We identified 5368 phosphopeptide-spectral matches (Additional file 2: Table S1) with a false discovery rate (FDR) of 1 %. Data acquired in triplicate showed good correlation (Pearson correlation coefficient 0.8) (Fig. 3a). PhosphoRS probability cutoff of 75 % was used for unambiguous localization of phosphorylation sites which lead to the identification of 672 unique phosphopeptides corresponding to 627 phosphorylation sites mapping to 359 proteins (Additional file 3: Table S2). Using 1.5-fold cutoff for hyperphosphorylation and 0.67-fold cutoff for decreased phosphorylation (hypophosphorylation) events, we identified 265 hyperphosphorylated and 40 hypophosphorylated phosphopeptides upon curcumin treatment. These curcumin-regulated phosphopeptides correspond to 187 proteins.

**Functional analysis of curcumin regulated phosphoproteome**

Since we observed widespread signaling alterations upon curcumin treatment, we next performed bioinformatics analysis of the differentially phosphorylated proteins to categorize them based on their cellular localization and
biological function. The classifications were based on annotations in HPRD, a Gene Ontology (GO) compliant database [38, 43]. Our analysis revealed that majority of the curcumin regulated proteins were localized in the cytoplasm (43 %) followed by plasma membrane (24 %), nucleus (19 %) and cytoskeleton (5 %) (Additional file 1: Fig. S1B). The proteins which were found to be differentially expressed upon curcumin exposure

Fig. 1 Curcumin treatment leads to decrease in invasive property and colony formation ability. a Colony formation assay following treatment of CAL 27 cells with curcumin or vehicle (DMSO). b A graphical representation of the colony forming ability of the CAL 27 cells upon treatment with curcumin or vehicle (DMSO). c CAL 27 cells were treated with either curcumin or vehicle (DMSO) for 48 h and invasive property of the cells were monitored. Cells that migrated are visualized using methylene blue. d A graphical representation of the invasive ability of the CAL 27 cells in presence of curcumin or vehicle (DMSO). e Phosphotyrosine profile of CAL 27 cells treated with curcumin for 0, 1 and 4 h analyzed by Western blotting using anti-phosphotyrosine antibody (Cat # 16-316).
were involved in a broad range of molecular functions. Majority of the proteins were found to be involved in catalytic activity, binding activity, and enzyme regulatory activity (Additional file 1: Fig. S1C). A major category (16%) of proteins regulated by curcumin were adaptor proteins. These include GRB2-associated-binding protein (GAB1), GRB2-associated-binding protein 2 (GAB2), SH2 domain-containing adapter protein B (SHB) and phosphoprotein membrane anchor with glycosphingolipid microdomains 1 (PAG1) that were differentially phosphorylated upon curcumin treatment. The other major categories of proteins identified were kinases (15%), cytoskeletal proteins (14%), membrane and cell junction proteins (13%) and the transport/carryer proteins. Classification based on the biological process revealed that majority of the proteins regulated by
curcumin were involved in cell communication (44%), followed by cell growth (18%) and metabolic processes (12%). (Additional file 1: Fig. S1D). We also employed Ingenuity Pathway analysis (IPA) analysis tool to group differentially phosphorylated proteins into networks and canonical pathways to determine altered cellular activities upon curcumin treatment. The top networks identified through this analysis included cellular movement, cancer and cellular development, cell-to-cell signaling and interaction. The proteins identified in the most significant biological network correlate with FAK and PI3K signaling pathways (Table 1).

Motif analysis was carried out to find over-representation of motifs among differentially phosphorylated sequence up on curcumin treatment. Motif analysis using motif-X algorithm enabled identification of two distinct phosphorylation motifs “pYxxP” and “pYG” (Fig. 3b). pYxxP is a proline directed motif where tyrosine is followed by a proline at +3 position and is known to be the recognition motif for phosphorylation by ABL kinase (ABL1). ABL kinase plays an important role in the regulation of cell proliferation, migration and cell survival [44], pYG is a glycine directed motif where tyrosine is followed by glycine at +1 position and is a known motif for phosphorylation by Src and Lck kinases. Src family kinases (SFKs) are known to be involved in cell growth, division, migration, and survival signaling pathways [45].

**Protein kinases and phosphatases altered in curcumin-mediated signaling**

Protein kinases and phosphatases play a critical role in the regulation of signaling networks. In this study, we identified 205 proteins which were differentially phosphorylated upon curcumin treatment. This involved 29 protein kinases including TNK2, FRK and AXL and 6 protein phosphatases such as PTPN6, PTPN11, PTPRK and INPPL1. Of these, the role of 18 protein kinases and 5 protein phosphatases have not been reported previously in curcumin-mediated signaling. A partial list of protein kinases and phosphatases altered on curcumin treatment has been listed in Table 2.

Amongst the protein kinases regulated by curcumin, we identified receptor tyrosine kinases including AXL, ERBB2 and EPHA1. Overexpression of AXL has been reported in various cancers such as thyroid carcinoma [46], renal cell carcinoma [47] and esophageal adenocarcinoma [48]. It is reported to be a potential biomarker for both early diagnosis and prognosis of oral squamous cell carcinoma [49]. Expression of AXL inversely correlates with survival of breast cancer patients with primary tumor and metastasis [50]. Our data indicates decrease in phosphorylation of AXL at Y598 upon curcumin treatment [Fig. 4a (i)]. Y598 is located in the tyrosine kinase domain of the AXL and can play an important role in the activation of tyrosine kinase activity of AXL to angiogenic responses and tumor neovascularization [51]. We also identified several members of MAPK signaling pathway to be differentially phosphorylated upon curcumin treatment. MAPK signaling has been shown to regulate cellular proliferation, particularly via the ERK-1/2 pathway [52]. This signaling pathway plays an important role in the growth, development, proliferation, and malignant transformation of cells. ERK-1/2 pathway is aberrantly activated in a variety of tumors and facilitates invasion and metastasis through activation of downstream effectors [53]. Curcumin is known to inhibit phosphorylation of ERK1/2 in CNE-2Z cells in a dose dependent manner [54]. We observed a decreased phosphorylation of the conserved residues T202/Y204 of ERK1/2 (MAPK3) upon curcumin treatment which is corroborated by western blot analysis as well (Fig. 4b).

In addition to kinases, we also observed alterations in the activity of multiple phosphatases upon curcumin treatment. Hyperphosphorylation of...
several phosphatases including, protein phosphatase 1 (PPP1CB), protein tyrosine phosphatase, non-receptor type 6 (PTPN6) and protein tyrosine, non-receptor type 11 (PTPN11) was observed upon curcumin treatment. PPP1CB and PPP1CA [Fig. 4a (ii)] are catalytic subunits of protein phosphatase 1 PP1, a serine/threonine specific protein phosphatase involved in the regulation of cell division and glycosin metabolism. PPP1CA is known to cause cell cycle arrest thereby preventing oncogenic transformation [55]. PTPN6 and PTPN11 are members of the protein tyrosine phosphatase (PTP) family. PTPs are involved in regulation of cell growth, differentiation, mitotic cycle, and oncogenic transformation. PTPN6 suppresses cancer cell growth and increases apoptosis [56]. It has also been reported to be downregulated in prostate cancer [57–59]. PTPN11 is known to be over-expressed in breast [60], cervical [61], laryngeal [62] and gastric cancers [63] but down regulated in colon cancer [64].

### Identification of novel molecules involved in curcumin-mediated signaling

In addition to molecules reported in literature to be regulated by curcumin, we identified several kinases which have not been reported previously in curcumin-mediated signaling. One such molecule is pseudopodium-enriched atypical kinase 1 (PEAK1) which is a member of the new kinase family three (NFK3) family. It plays an important role in regulation of cell migration, proliferation and cancer metastasis [65]. We identified a two-fold decrease in phosphorylation of PEAK1 at Y635 upon curcumin treatment. Further, phosphorylation of PEAK1 at Y635 is associated with acinar growth and cell invasion [66]. A member of the TYR family of protein kinase, Fyn-related

| Gene symbol | Protein                     | Site       | Phosphopeptide sequence         | Fold change (curcumin/DMSO) |
|-------------|----------------------------|------------|---------------------------------|----------------------------|
| PTPN6       | Tyrosine-protein phosphatase non-receptor type 6 | Y536       | GQESyGNITYPPAMK                 | 5.1                         |
| ABL2        | Abelson tyrosine-protein kinase 2                  | Y647       | yELGLPLEQDR                     | 4.4                         |
| INPP1       | Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 | Y986       | NSFNNPAPyYLEGYPQHLPPPPPSPAR     | 2.8                         |
| MAPK11      | Mitogen-activated protein kinase 11                | Y182       | QADEEMTgyVATR                   | 2.2                         |
| PTPRK       | Receptor-type tyrosine-protein phosphatase kappa   | Y858       | CEGTESPyQTQGLHPAAR              | 2.5                         |
| FRK         | Fyn-related Src family tyrosine kinase             | Y497       | LEDYFETDSySDANNFIR              | 0.5                         |
| PEA1K       | Pseudopodium enriched atypical kinase 1            | Y635       | IVINPNyDNLAIYK                  | 0.5                         |
| TNK2        | Activated CDC42 kinase 1                           | Y827       | yATPQVQAPGPR                    | 0.5                         |
| AXL         | Tyrosine-protein kinase receptor UFO               | Y598       | yVLCPSTIPSPQPAQR                | 0.5                         |
| PTPRE       | Receptor-type tyrosine-protein phosphatase epsilon | Y638       | WQDIDIFSyDyANFK                 | 0.5                         |
Fig. 4 Curcumin regulated phosphoproteome. **a** Representative MS spectra of phosphorylated kinases/phosphatases. **a** i, iii, phosphorylation of peptides on kinases (AXL and FRK). **a** ii, iv, phosphatases (PPP1CA and PTPRK) was differentially phosphorylated as evidenced by MS spectra showing the changes in the relative abundance of phosphopeptides. **b** Proteins identified to be differentially phosphorylated upon curcumin treatment from our mass spectrometry data were validated by Western blot using anti-phospho antibodies for pEPHA2 (Y772) and pMAPK1/MAPK3 (T202/Y204). Total expression was probed using anti-EPHA2 and anti-MAPK1/MAPK3.
Src family tyrosine kinase (FRK), also showed a two-fold decrease in phosphorylation at Y497 upon curcumin treatment [Fig. 4a (iii)]. FRK is a non-receptor protein tyrosine-kinase and is known to be involved in migration and invasion. Although there are several reports on the site being phosphorylated, the significance of the phosphorylation site and its role in the function of FRK is currently unknown. Although several sites on kinases were observed to be hypophosphorylated by curcumin, in the case of EPHA2, a member of Eph receptor tyrosine kinase family; we observed a 1.7 fold increase in the phosphorylation levels at Y772. This is further supported by Western blot analysis, which shows hyper-phosphorylation of EPHA2 at Y772 in the presence of curcumin (Fig. 4b).

Protein tyrosine phosphatases are known to regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. PTPRK is a protein tyrosine phosphatase (PTP) that is known to regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation [67, 68]. It negatively regulates STAT3 phosphorylation at Y705 [69]. Upon curcumin exposure, STAT3 phosphorylation decreases at Y705 [65]. In our analysis, phosphorylation of PTPRK at Y858 increased two fold upon curcumin exposure [Fig. 4a (iv)], indicating curcumin regulates STAT3 phosphorylation through PTPRK.

Some of the phosphatases regulated by curcumin and reported for the first time in this study include protein tyrosine phosphatase, receptor type, E (PTPRE) and PTPN6. PTPRE phosphorylation at Y638 is necessary for its activation and regulates the activity of c-SRC. The activity of c-Src is important for maintaining malignant transformation of tumor cells [66]. Our data demonstrates that curcumin can effectively inhibit PTPRE phosphorylation at Y638. Further, c-Src has been reported to phosphorylate GRB2-associated binding protein 1 (GAB1) at Y406 and mediate growth-factor signaling [70]. GAB1 plays a central role in cellular growth response, transformation and apoptosis. Down regulation of GAB1 reduces proliferation and migration in cholangiocarcinoma [71]. Our data shows a two-fold decrease in phosphorylation of GAB1 at Y406 upon curcumin treatment.

Curcumin induced signaling and apoptosis
Curcumin induces programmed cell death (apoptosis) in many cancer cell types. In our data we identified differential phosphorylation of multiple proteins by curcumin, which have been previously reported in literature to be involved in apoptosis of cancer cells. Caveolin-1 (CAV-1) is a major integral membrane protein on caveolae and its loss of function leads to tumorigenesis. It is known that several drugs such as bromocriptine and taxol increase the phosphorylation of caveolin-1 at Y14 leading to apoptosis in pituitary adenoma and breast cancer [72, 73]. Interestingly, in our analysis we observed a fourfold increased phosphorylation of caveolin-1 at Y14. Further studies are needed to understand the exact mechanism of curcumin-induced phosphorylation of caveolin and its role in apoptosis, which is beyond the scope of this study. Members of the MAPKs family regulate diverse signal transduction pathways that control multiple aspects of cellular physiology, including cell growth, differentiation, and apoptosis [74]. Stress responsive signals have been shown to activate MAPK9, MAPK10 and MAPK12. Drugs such as doxorubicin, apilidin and resveratrol increase phosphorylation of MAPK9 and MAPK12 at Y185 and induce apoptosis [74]. In our data, both MAPK9 and MAPK12 were hyperphosphorylated two and threefold respectively at Y185 in the presence of curcumin.

Curcumin mediated FAK signaling
The most significant biological networks identified in IPA analysis (Table 2) which received an IPA score of 37, included several proteins that were differentially expressed in our data and correlated with FAK signaling pathway. FAK is a cytoplasmic tyrosine kinase which influences various signaling pathways that promote cancer growth and metastasis. It controls cell motility, invasion and cell survival [75–77]. Curcumin inhibits phosphorylation of FAK and affects the expression of several extracellular matrix components which play an important role in invasion and metastasis [78]. In agreement with previous studies, we observed curcumin-mediated decreased phosphorylation of FAK at Y397 and Y407. Studies indicate that hyper-activation of FAK through phosphorylation at these sites leads to migration, proliferation and invasion of cells [79–81]. Although inhibition of FAK activation through curcumin is well studied minimal information is available about its downstream signaling. Based on manual literature curation and functional analysis, we identified several proteins, such as CAV1, PI3 K and ERK1 in the focal adhesion pathway (Fig. 5a). Our data shows a four-fold increase in the phosphorylation of CAV1 at Y14 upon curcumin treatment. It is known that over expression of CAV1 reduces the expression of integrin β3 and activity of FAK [82]. Phosphorylation of FAK in response to integrin leads to the formation of phosphotyrosine docking sites for Paxillin which in turn phosphorylates CRK leading to complex formation with DOCK1/ELMO, which ultimately regulates cell migration [83]. FAK also interacts with SHC1 which then recruits SOS1, HRAS, BRAF and activates...
Fig. 5 Curcumin regulated signaling networks. a Pathway analysis of proteins differentially phosphorylated upon curcumin treatment indicated enrichment of focal adhesion pathway. Proteins identified in this study regulated by curcumin are represented in red (hyperphosphorylated) or green (hypophosphorylated). b Ingenuity network analysis of phosphoproteins regulated by curcumin reveals enrichment of NF-κB sub-network. Solid lines represent protein–protein interactions, dashed lines with an arrow represent enzymatic reactions and solid lines with an arrow represent both protein-protein interactions and enzymatic reactions.
Additional files

Additional file 1: Figure 1. (A) Cell viability of CAL 27 with indicated concentrations of curcumin. Classification of differentially phosphorylated proteins based on (B) Localization (C) Biological process (D) Molecular function.

Additional file 2: Table S1. A list of phosphoPSMs identified by MASCOT and SEQUEST.

Additional file 3: Table S2. A list of phosphopeptides quantitated by SILAC.

Abbreviations

HNSCC: head and neck squamous cell carcinoma; IAP: immunoaffinity purification; SILAC: stable isotope labeling by amino acid in cell culture.

Authors’ contributions

AC and GS conceived the idea and planned the study. VN and NS carried out cell culture. GS, SR, RSN carried out sample preparation. GS carried out mass spectrometry analysis. GS and SMP analysed mass spectrometry derived data and western blotting. AAK performed pathway analysis. GS, SMP and SC prepared figures and tables. GS and AHP carried out bioinformatics analysis. HSS performed motif analysis. GS, SMP, AC wrote the manuscript. HG, AC, TSKP, BN and PPM provided critical inputs and revised the manuscript. All authors read and approved the final manuscript.

Author details

1 Institute of Bioinformatics, Unit I, 7th Floor, Discoverer Building, International Tech Park, Bangalore 560066, India. 2 Manipal University, Madhav Nagar, Manipal 576104, India. 3 YU-IOB Center for Systems Biology and Molecular Medicine, Yenepoya University, Mangalore 575018, India. 4 Department of Biochemistry and Molecular Biology, Pondicherry University, Puducherry 605014, India. 5 Amrita School of Biotechnology, Amrita University, Kollam 690525, India. 6 School of Biotechnology, KIT University, Bhubaneswar 751024, India. 7 Centre of Excellence in Bioinformatics, School of Life Sciences, Pondicherry University, Puducherry 605014, India. 8 NIMHANS-IOB Proteomics and Bioinformatics Laboratory, Neurobiology Research Centre, National Institute of Mental Health and Neurosciences, Bangalore 560029, India.

Acknowledgements

We thank the Department of Biotechnology (DBT), Government of India for research support to the Institute of Bioinformatics (IOB), Bangalore. We thank the “Infosys Foundation” for research support to IOB. This work was supported by the Science and Engineering Research Board, Department of Science and Technology, Government of India grant “mRNAs in chronic tobacco-induced oral cancer (SR/SO/HS-02081/2012)” and Role of mRNA in promoting lung cancer in response to cigarette smoke(SERC/LS-439/2001), NCI’s Clinical Proteomic Tumor Analysis Consortium initiative (U24CA160036) and FAMRI-funded 07/2017_YCSC. GS, SC, are recipients of Senior Research Fellowship from Council of Scientific and Industrial Research (CSIR), Government of India. SMP is a recipient of INSPIRE faculty Award from Department of Science and Technology (DST), Government of India. NS is recipient of Senior Research Fellowship from the University Grants Commission (UGC), India. AAK is recipient of Senior Research Fellowship from Indian Council of Medical Research (ICMR), Government of India. We thank Department of Health and Family Welfare for procuring Orbitrap Fusion instrument at NIMHANS-IOB laboratory. We thank Dr. S. K. Shankar and Dr. Anita Mahadevan of NIMHANS, for providing access to the microscopy imaging facility.

Competing interests

The authors declare that they have no competing interests.

Received: 1 January 2016 Accepted: 4 May 2016

Published online: 15 June 2016

References

1. Rao CV, Rivenson A, Simi B, Reddy BS. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 1995;55(2):259–66.

2. Farazuddin M, Dua B, Zia Q, Khan AA, Joshi B, Owais M. Chemotherapeutic potential of curcumin-bearing microcells against hepatocellular carcinoma in model animals. Int J Nanomed. 2014;9:1139–52. doi:10.2147/IJN.S34668.

3. Seejayan Rao MN. Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol. 1994;46(12):1013–6.

4. Li Q, Chen J, Luo S, Xu J, Huang Q, Liu T. Synthesis and assessment of the antioxidant and antitumor properties of asymmetric curcumin analogues. Eur J Med Chem. 2015;93C:461–9. doi:10.1016/j.ejmech.2015.02.005.

5. Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal. 2008;10(3):S11–45. doi:10.1089/ars.2007.1769.

6. Sahibaie P, Sun Y, Liang DY, Shi XY, Clark JD. Curcumin treatment attenuates pain and enhances functional recovery after incision. Anesth Analg. 2014;118(6):1336–44. doi:10.1213/ANE.0000000000000189.

7. Rana C, Pipani H, Vaish Y, Nehru B, Sanjal SN. Downregulation of telomerase activity by diclofenac and curcumin is associated with cell cycle arrest and induction of apoptosis in colon cancer. Tumour Biol. 2015. doi:10.1007/s13277-015-2326-7.
8. Ramachandran C, Fonseca HB, Jhabvala P, Escalon EA, Melnick SJ. Curcumin inhibits telomerase activity through human telomerase reverse transcriptase in MCF-7 breast cancer cell line. Cancer Lett. 2002;184(1):1–6.

9. Dorai T, Gao YC, Dorai B, Buttyan R, Katz AE. Therapeutic potential of curcumin in human prostate cancer III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate. 2001;47(4):293–303. doi:10.1002/pro.1074.

10. Yu J, Zhou X, He X, Dai M, Zhang Q. Curcumin induces apoptosis involving bax/bcl-2 in human hepatoma SMA-7721 cells. Asian Pac J Cancer Prev. 2011;12(8):1925–9.

11. Cai XZ, Huang WY, Qiao Y, Du SY, Chen Y, Chen D, et al. Inhibitory effects of curcumin on gastric cancer cells: a proteomic study of molecular targets. Phytomedicine. 2013;20(6):495–505. doi:10.1016/j.phymed.2012.12.007.

12. Wang JB, Qi LL, Zheng SD, Wu TX. Curcumin induces apoptosis through the mitochondria-mediated apoptotic pathway in HT-29 cells. J Zhejiang Univ Sci B. 2009;10(2):93–102. doi:10.1631/jzus.0802038.

13. Gogada R, Amadon M, Zhang H, Jones A, Verone A, Pitarresi J, et al. Curcumin induces Apat-1-dependent, p21-mediated caspase activation and apoptosis. Cell Cycle. 2011;10(23):4128–37. doi:10.4161/cc.21892.

14. Shankar S, Chen Q, Sarva K, Siddiqui I, Srivastava RK. Curcumin enhances survival signaling pathways in human leukemia THP-1 cells. Pharmazie. 2011;66(3):229–33. doi:10.1691/ph.2011.0014.

15. Chen A, Xu J, Johnson AC. Curcumin inhibits human colon cancer cell growth by suppressing expression of epidermal growth factor receptor through reducing the activity of the transfection factor Egr-1. Oncogene. 2006;25(2):278–87. doi:10.1038/sj.onc.1209019.

16. Hong RL, Spohn WH, Hung MC. Curcumin inhibits tyrosine kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53. Int J Oncol. 1999;14(3):499–503.

17. Rappsilber J, Ishihama Y, Mann M. Stop and go extraction tips for quantitative phosphoproteomics. Nat Methods. 2015;12(7):629–31. doi:10.1038/nmeth.3562.

18. Prasad TS, Kandasamy K, Pandey A. Human Protein Reference Database and Human Proteinpedia as discovery tools for systems biology. Methods Mol Biol. 2015;1281:297–307. doi:10.1007/978-1-4939-1920-3_19.

19. Hunter T. Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol. 2000;12(2):166–72. doi:10.1016/S0955-0674(00)00058-8.

20. Subbannayya Y, Syed N, Barbhuiya MA, Raja R, Marimuthu A, Sahasrabuddhe N, et al. Curcumin induces Apaf-1-dependent, p21-mediated caspase activation and apoptosis. Cell Cycle. 2011;10(23):4128–37. doi:10.4161/cc.21892.

21. Madden K, Flowers L, Salani R, Horowitz L, Logan S, Kowalski K, et al. PROTein Sequencing-based approach to elucidate the mechanism of antitumor effect of curcumin in cervical cancer. Prostaglandins Leukot Essent Fatty Acids. 2009;80(1):9–18. doi:10.1016/j.plfa.2008.10.003.

22. Journal of Proteome Research. 2009;8(1):102–110. doi:10.1021/pr800982y.

23. Hunter T. Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol. 2000;12(2):166–72. doi:10.1016/S0955-0674(00)00058-8.
65. Wang Y, Kelber JA, Tran Cao HS, Cantin GT, Lin R, Wang W, et al. Pseudopodia are required for cell migration and invasion in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res. 2009;15(14):4742–9. doi:10.1158/1078-0432.CCR-08-2514.

66. Croucher DR, Hochgrafe F, Zhang L, Liu L, Lyons RJ, Rickwood D, et al. Involvement of Lyn and the atypical kinase Src in basal breast cancer signaling pathway. Cancer Res. 2013;73(6):1969–80. doi:10.1158/0008-5472.CAN-12-1472.

67. Sun NH, Ye L, Mason MD, Jiang WG, Du JB, Wang JS, et al. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther. 2010;10(10):1009–18. doi:10.4161/cbt.10.10.13248.

68. Lee CH, Yen CY, Liu SY, Chen CK, Chang CF, Shiau SG, et al. Axl is a prognostic marker in oral squamous cell carcinoma. Ann Surg Oncol. 2012;19(Suppl 9):S500–6. doi:10.1245/s10434-011-1985-8.

69. Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T, et al. Icariside II and clinical significance of tyrosine phosphatase SHP-2 in gastric cancer. J Int Med Res. 2012;40(4):986–93. doi:10.1177/0300060512454892.

70. Tassidis H, Culig Z, Wingren AG, Harkonen P. Role of the protein tyrosine phosphatase SHP2 in breast cancer metastasis and patient survival. Proc Natl Acad Sci USA. 2010;107(3):1124–9. doi:10.1073/pnas.0909331107.

71. Sang H, Li T, Li H, Liu J. Down-regulation of Gab1 inhibits cell proliferation and migration in hiliar cholangiocarcinoma. PLoS One. 2013;8(11):e78137. doi:10.1371/journal.pone.0078137.

72. Qin JL, Baron K, Al-Zahrani KN, O'Reilly P, Sriram RK, Conway J, et al. SLK-1 inhibits cell growth by promoting degradation of JAK kinases. J Cell Biochem. 2012;113(2):379–90. doi:10.1002/jcb.24541.

73. Shibue T, Brooks RD, Li MF, Johannsen A, Cai Y, Guo T, et al. CAV1 inhibits metastatic potential in melanomas through DOCK180. J Cell Biol. 2010;188(5):989–1001. doi:10.1083/jcb.200911012.

74. Cance WG, Golubovskaya VM. Focal adhesion kinase versus p53: apoptosis or survival? Science signaling. 2008;1(200):pe22. doi:10.1126/sciadvances/2012.120pe22.

75. Mitra SK, Han DA, Schlaeffer DD. Focal adhesion kinase: in control of drug resistance. Nat Rev Mol Cell Biol. 2005;6(1):56–68. doi:10.1038/nrm1549.

76. Guo T, Zhang L, Liu L, Lyons RJ, Rickwood D, et al. Involvement of Lyn and the atypical kinase Src in basal breast cancer signaling pathway. Cancer Res. 2013;73(6):1969–80. doi:10.1158/0008-5472.CAN-12-1472.

77. Sang H, Li T, Li H, Liu J. Down-regulation of Gab1 inhibits cell proliferation and migration in hiliar cholangiocarcinoma. PLoS One. 2013;8(11):e78137. doi:10.1371/journal.pone.0078137.

78. Qin JL, Baron K, Al-Zahrani KN, O'Reilly P, Sriram RK, Conway J, et al. SLK-1 inhibits cell growth by promoting degradation of JAK kinases. J Cell Biochem. 2012;113(2):379–90. doi:10.1002/jcb.24541.

79. Sang H, Li T, Li H, Liu J. Down-regulation of Gab1 inhibits cell proliferation and migration in hiliar cholangiocarcinoma. PLoS One. 2013;8(11):e78137. doi:10.1371/journal.pone.0078137.

80. Sang H, Li T, Li H, Liu J. Down-regulation of Gab1 inhibits cell proliferation and migration in hiliar cholangiocarcinoma. PLoS One. 2013;8(11):e78137. doi:10.1371/journal.pone.0078137.

81. Mukhopadhyay NK, Gordon GJ, Chen CJ, Bueno R, Sugarbaker DJ, Jakubowska A, et al. SLK-1 inhibits cell growth by promoting degradation of JAK kinases. J Cell Biochem. 2012;113(2):379–90. doi:10.1002/jcb.24541.

82. Qin JL, Baron K, Al-Zahrani KN, O'Reilly P, Sriram RK, Conway J, et al. SLK-1 inhibits cell growth by promoting degradation of JAK kinases. J Cell Biochem. 2012;113(2):379–90. doi:10.1002/jcb.24541.

83. Sang H, Li T, Li H, Liu J. Down-regulation of Gab1 inhibits cell proliferation and migration in hiliar cholangiocarcinoma. PLoS One. 2013;8(11):e78137. doi:10.1371/journal.pone.0078137.

84. Schlaepfer DD, Hunter T. Focal adhesion kinase overexpression enhances tumor progression. Cancer Res. 1998;58(14):3171–5. doi:10.1158/0008-5472.CAN-97-1301.
85. Xu X, Qin J, Liu W. Curcumin inhibits the invasion of thyroid cancer cells via down-regulation of PI3K/Akt signaling pathway. Gene. 2014;546(2):226–32. doi:10.1016/j.gene.2014.06.006.
86. Wu J, Li Y, Dang YZ, Gao HK, Jiang JL, Chen ZN. HAb18G/CD147 promotes radioresistance in hepatocellular carcinoma cells: a potential role for integrin beta1 signaling. Mol Cancer Ther. 2014. doi:10.1158/1535-7163.MCT-14-0618.
87. Niu G, Ye T, Qin L, Bourbon PM, Chang C, Zhao S, et al. Orphan nuclear receptor TR3/Nur77 improves wound healing by upregulating the expression of integrin beta4. FASEB J. 2015;29(1):131–40. doi:10.1096/fj.14-257550.
88. Eulenfeld R, Schaper F. A new mechanism for the regulation of Gab1 recruitment to the plasma membrane. J Cell Sci. 2009;122(Pt 1):55–64. doi:10.1242/jcs.037226.